Dual effect of anchored sulphur and activated oxygen in the catalytic oxidation of organic sulfur over Pt single-atom catalysts

Tian Tang(University of Alberta), Honghong Yi(University of Science and Technology Beijing), Ronghui Zhu(University of Science and Technology Beijing), Kai Chen(Beihang University), Long Sun(University of Science and Technology Beijing), Shunzheng Zhao(University of Science and Technology Beijing), Guang Mo(Institute of High Energy Physics), Yunpeng Liu(Shenyang Institute of Automation), Xiaolong Tang(Guizhou University)
Journal of Colloid and Interface Science
February 23, 2025
10.1016/j.jcis.2025.02.160
Cited by 4

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
|The Lancet Oncology|2015|412